Comparison of Immunogenicity and Safety of DTP-HB-Hib (Bio Farma) With Pentabio® Vaccine Primed With Recombinant Hepatitis B

Inclusion Criteria: * Healthy, full term, newborns infants. * Infant born after 37-42 weeks of pregnancy. * Infant weighing 2500 gram or more at birth. * Father, mother or legally acceptable representative properly informed about the study and having signed the informed consent form. * Parents will commit themselves to comply with the indications of the investigator and with the schedule of the trial. Exclusion Criteria: * Child concomitantly enrolled or scheduled to be enrolled in another trial. * Mother with HBsAg positive. * Evolving mild, moderate or severe illness, especially infectious diseases or fever (axillary temperature \>37.5C on Day 0). * Suspected of allergy to any component of the vaccines (e.g. formaldehyde). * Suspected of uncontrolled coagulopathy or blood disorders contraindicating intramuscular injection. * Newborn suspected of congenital or acquired immunodeficiency (including HIV infection). * Received or plans to receive any treatment likely to alter the immune response (intravenous immunoglobulins, blood-derived products or long term corticotherapy (\> 2 weeks)). * Received other vaccination with the exception of BCG and poliomyelitis. * Any abnormality or chronic disease which according to the investigator might interfere with the assessment of the trial objectives.